Schedule 13D ownership disclosure

LENZ THERAPEUTICS INC

Common Stock, par value $0.00001 per share · CUSIP: 52635N103

Event date: 2025-08-18

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Versant Venture Capital VI, L.P.Reported CIK 0001687880

    Shares: 1,400,220 · Class: 4.9%

  • Versant Ventures VI GP, L.P.Reported CIK 0001777654

    Shares: 1,400,220 · Class: 4.9%

  • Versant Ventures VI GP-GP, LLCReported CIK 0001777652

    Shares: 1,400,220 · Class: 4.9%

  • Versant Vantage II, L.P.Reported CIK 0001832235

    Shares: 842,162 · Class: 3.0%

  • Versant Vantage II GP, L.P.Reported CIK 0001839790

    Shares: 842,162 · Class: 3.0%

  • Versant Vantage II GP-GP, LLCReported CIK 0001839789

    Shares: 842,162 · Class: 3.0%

  • Versant Venture Capital VII, L.P.Reported CIK 0001750266

    Shares: 1,033,412 · Class: 3.6%

  • Versant Ventures VII GP, L.P.Reported CIK 0001777655

    Shares: 1,033,412 · Class: 3.6%

  • Versant Ventures VII GP-GP, LLCReported CIK 0001777656

    Shares: 1,033,412 · Class: 3.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-25-110483
Form type
SCHEDULE 13D/A
Filer
LENZ Therapeutics, Inc.
CIK
CIK 1815776
Filed
Aug 20, 2025
Reporting period
Aug 18, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub